Pfizer’s 20-valent pneumococcal vaccine to receive FDA priority review

The new vaccine candidate comprises capsular polysaccharide conjugates for the 13 serotypes already included in Pfizer’s Prevnar 13, as well as capsular polysaccharide conjugates for seven additional serotypes that cause invasive pneumococcal disease

Source:

PharmaTimes